profit from every $100 of sales.
$0$100
Fonar
We have no price for Fonar since 3 June 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$19.09+0.00% today
+22.2% since Oct 10, 25
1-year low $14.031-year high $19.11
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $14.42 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Fonar sold, what it kept, and what it did with the cash.
Sales went from $97.6 million in 2022 to $104 million in 2025, with $8.33 million of profit last year.
SalesProfit
Fonar handed back 24% of the cash it generated last year.
Buybacks $2M
Free cash flow 2025$7M
Bought back its own shares$2M
Paid as dividends–
Cash vs. debt$56M vs. $39M
Fonar vs. similar companies
Fonar grows in the middle of these 5 and is the cheapest for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Fonar | 14.4× · Cheap | ||
 Concentra Group Holdings Parent | 32.1× · Expensive | ||
 Hims & Hers Health | 36.0× · Expensive | ||
 Envista | 83.5× · Very expensive | ||
 Beta Bionics | No profit yet |
AI analysis
An AI analyst reads Fonar's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 98 | 99 | 103 | 104 | |
| 47 | 46 | 45 | 43 | |
| 22 | 15 | 17 | 12 | |
| 32 | 25 | 24 | 19 | |
| 12 | 9 | 11 | 8 | |
| 1.75 | 1.32 | 1.53 | 1.23 | |
| 48.2% | 46.4% | 43.9% | 41.1% | |
| 22.6% | 15.0% | 16.1% | 11.1% | |
| 12.7% | 9.5% | 10.3% | 8.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 199 | 201 | 214 | 217 |
| Cash | 49 | 51 | 56 | 56 |
| Total debt | 38 | 37 | 42 | 39 |
| Total liabilities | 53 | 50 | 57 | 57 |
| 150 | 158 | 166 | 173 | |
| 7 | 7 | 6 | 6 | |
| 9.7% | 6.4% | 7.4% | 5.2% | |
| 8.3% | 5.9% | 6.4% | 4.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 15 | 14 | 14 | 11 | |
| 5 | 4 | 1 | 4 | |
| 11 | 10 | 13 | 7 | |
| Dividends paid | – | – | – | – |
| 0 | 2 | 3 | 2 | |
| 0 | – | – | – |
Valuation
- 14.4×
- –
- –
- –
- 1.2×
- 16.1×
- 5.6×
- 6.2%
- 6.9%
- –
Profitability
- 41.1%
- 11.1%
- 8.0%
- –
- –
- –
- –
- –
- –
- –
Growth
- +2.3%
- −11.1%
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 45%of 872
Top 18%of 564
Bottom 20%of 867
Top 15%of 986
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | 0.24 | – | – |
| Feb 13, 2026 | 0.31 | – | – |
| Nov 10, 2025 | 0.34 | – | – |
| Sep 22, 2025 | 0.11 | – | – |
| May 15, 2025 | 0.37 | – | – |
| Feb 19, 2025 | 0.29 | – | – |
| Nov 12, 2024 | 0.46 | – | – |
| Sep 27, 2024 | 0.13 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
35No pass
Benjamin Graham
43No pass
Philip Fisher
17No pass
Peter Lynch
12No pass
Joel Greenblatt
14No pass
Charlie Munger
21No pass
Terry Smith
22No pass
Questions about Fonar
Is Fonar a good stock to buy?
A business with weak numbers, and the price looks low. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Fonar AI analysis
What does Fonar do?
FONAR Corporation, together with its subsidiaries, engages in the designing, manufacturing, selling, and servicing of magnetic resonance imaging (MRI) scanners for the detection and diagnosis of human diseases, abnormalities, other medical conditions, and injuries in the United States. It is in Medical - Equipment & Services.
Does Fonar pay a dividend?
No. Fonar does not pay a dividend at the moment; in 2025 it returned $1.81 million to shareholders by buying back its own shares.
Who are Fonar's competitors?
The largest listed companies in the same industry are Concentra Group Holdings Parent, Hims & Hers Health, Envista and Beta Bionics. The peers table on this page compares their profit, growth and price with Fonar's.
Prices: daily closes to Jun 3, 2026. Fundamentals: company reports via invest-like data.